These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 31815839)

  • 1. Acceptability and Feasibility of Using Raltegravir Oral Granules for the Treatment of Neonates in a Low-resource Setting.
    Archary M; Zanoni B; Lallemant M; Suwannaprom P; Clarke D; Penazzato M
    Pediatr Infect Dis J; 2020 Jan; 39(1):57-60. PubMed ID: 31815839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Health Literate Patient-focused Approach to the Redesign of the Raltegravir (ISENTRESS) Pediatric Kit and Instructions for Use.
    Mills A; Myers L; Raudenbush C; Vossen DA; Teppler H; Miteva YR; Seeley S; Homony B; Straus WL
    Pediatr Infect Dis J; 2022 Jan; 41(1):51-56. PubMed ID: 34694252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising neonatal antiretroviral therapy using raltegravir: a qualitative analysis of healthcare workers' and caregivers' perspectives.
    Katirayi L; Stecker C; Andifasi P; Mushavi A; Tiwari P; Jakazi C; Maphosa T; Thorsen V; Murandu M; Gombakomba G; Mungati M; Denoeud-Ndam L; Rivadeneira E; Weber R; Hrapcak S
    BMJ Paediatr Open; 2022 Jul; 6(1):. PubMed ID: 36053612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Five years' real-life experience with raltegravir in a large HIV centre.
    van Halsema C; Whitfield T; Lin N; Ashton K; Torkington A; Ustianowski A
    Int J STD AIDS; 2016 Apr; 27(5):387-93. PubMed ID: 25931236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A safety evaluation of raltegravir for the treatment of HIV.
    de Miguel R; Montejano R; Stella-Ascariz N; Arribas JR
    Expert Opin Drug Saf; 2018 Feb; 17(2):217-223. PubMed ID: 29199485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir.
    Krishna R; East L; Larson P; Valiathan C; Butterfield K; Teng Y; Hernandez-Illas M
    J Pharm Pharmacol; 2016 Nov; 68(11):1359-1365. PubMed ID: 27671833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of raltegravir and raltegravir glucuronide in human plasma and urine by LC-MS/MS with application in a maternal-fetal pharmacokinetic study.
    Moreira FL; Marques MP; Duarte G; Lanchote VL
    J Pharm Biomed Anal; 2020 Jan; 177():112838. PubMed ID: 31525573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Treatment With Raltegravir is Associated with Lower Triglycerides and Platelets Count in the Older HIV+ Population: Results from the Ral-Age Study.
    Pavone P; Giustini N; Fimiani C; Paoletti F; Falciano M; Salotti A; Di Sora F; Al Moghazi S; Mezzaroma I; Vullo V; d'Ettorre G
    Curr HIV Res; 2017 Nov; 15(5):355-360. PubMed ID: 28969567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Modeling and Simulations to Determine Raltegravir Dosing in Neonates: A Model for Safely and Efficiently Determining Appropriate Neonatal Dosing Regimens: IMPAACT P1110.
    Clarke DF; Mirochnick M; Acosta EP; Capparelli E; Chain A; Teppler H; Smith B; Lommerse J;
    J Acquir Immune Defic Syndr; 2019 Dec; 82(4):392-398. PubMed ID: 31658182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Raltegravir in patients co-infected with HIV and HCV in the era of direct antiviral agents.
    Taramasso L; Cenderello G; Riccardi N; Tunesi S; Di Biagio A
    New Microbiol; 2017 Oct; 40(4):227-233. PubMed ID: 28994443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
    Krikke M; Tesselaar K; van den Berk GEL; Otto SA; Freriks LH; van Lelyveld SFL; Visseren FJL; Hoepelman AIM; Arends JE
    HIV Clin Trials; 2018 Apr; 19(2):75-83. PubMed ID: 29770748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection.
    Amin J; Boyd MA; Kumarasamy N; Moore CL; Losso MH; Nwizu CA; Mohapi L; Kerr SJ; Sohn AH; Teppler H; Renjifo B; Molina JM; Emery S; Cooper DA
    PLoS One; 2015; 10(2):e0118228. PubMed ID: 25723472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing uptake of HIV care and treatment among children in South Africa - a qualitative study of caregivers and clinic staff.
    Yeap AD; Hamilton R; Charalambous S; Dwadwa T; Churchyard GJ; Geissler PW; Grant AD
    AIDS Care; 2010 Sep; 22(9):1101-7. PubMed ID: 20824563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current status of the female condom in Africa].
    Deniaud F
    Sante; 1997; 7(6):405-15. PubMed ID: 9503499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucosal tissue pharmacokinetics of the integrase inhibitor raltegravir in a humanized mouse model: Implications for HIV pre-exposure prophylaxis.
    Veselinovic M; Yang KH; Sykes C; Remling-Mulder L; Kashuba AD; Akkina R
    Virology; 2016 Feb; 489():173-8. PubMed ID: 26771889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atazanavir increases the plasma concentrations of 1200 mg raltegravir dose.
    Krishna R; East L; Larson P; Valiathan C; Deschamps K; Luk JA; Bethel-Brown C; Manthos H; Brejda J; Gartner M
    Biopharm Drug Dispos; 2016 Dec; 37(9):533-541. PubMed ID: 27696440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
    Grinsztejn B; Nguyen BY; Katlama C; Gatell JM; Lazzarin A; Vittecoq D; Gonzalez CJ; Chen J; Harvey CM; Isaacs RD;
    Lancet; 2007 Apr; 369(9569):1261-1269. PubMed ID: 17434401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.